<DOC>
	<DOCNO>NCT01712789</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy generate PK biomarker data combination pomalidomide low-dose dexamethasone patient refractory relapse refractory multiple myeloma . The study consist Screening phase within 28 day prior cycle 1 day 1 , Treatment phase Follow-up phase start within 28 day discontinuation study treatment , every 3 month 5 year . In addition , collection steady-state PK data large population enable robust population PK ass Pomalidomide exposure response analyse . The exploratory objective study investigate potential marker predictive POM response resistance pharmacodynamic marker .</brief_summary>
	<brief_title>Evaluation Safety Pomalidomide Combination With Dexamethasone ( Low Dose ) Patients With Refractory Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients ≥18 year old , must understand voluntarily sign Informed Consent . Patients must document diagnosis Multiple Myeloma measurable disease . Patients must undergo prior treatment ≥ 2 treatment line , antimyeloma therapy . Patients must either refractory relapsed refractory disease . Patients must receive least 2 consecutive cycle prior treatment include lenalidomide bortezomib , either alone combination regimen . Patients must receive adequate alkylator therapy Prior history malignancy , Multiple Myeloma . Previous therapy Pomalidomide , hypersensitivity thalidomide lenalidomide dexamethasone . Patients receive allogeneic bone marrow allogeneic peripheral blood stem cell transplant . Patients plan eligible stem cell transplant . Patients receive major surgery antimyeloma drug therapy within last 14 day start study treatment . Patients current disease interfere protocol procedure study treatment . Patients unable unwilling undergo antithrombotic prophylactic treatment . Pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Relapsed refractory Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>